Trial Profile

A bioequivalence study of eldecalcitol comparing the soft capsule and the tablet in healthy adult volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eldecalcitol (Primary) ; Eldecalcitol
Indications Osteoporosis
Focus Pharmacokinetics; Registrational

Most Recent Events

21 Aug 2022 New trial record
15 Aug 2022 According to a Chugai Pharmaceutical media release, based on this trial the Ministry of Health, Labour and Welfare (MHLW) has approved Edirol Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for treatment of osteoporosis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com